LONDON, Sept 25 (Reuters) – British biotechnology company Adaptimmune has raised $104 million in venture capital to fund its work in developing a new range of drugs based on immune-system cells. The Oxford-based private company plans to use the money to advance its programmes to clinical trials against multiple types of cancer, it said on …
Year: 2014
Bellicum Pharmaceuticals Secures $55 Million in Oversubscribed Series C Financing
Investor syndicate includes leading biotech and mutual funds. HOUSTON–BUSINESS WIRE–Bellicum Pharmaceuticals, Inc., a biotechnology company focused on developing safer and more effective cellular immunotherapies, today announced the successful completion of a $55M Series C financing. The funding will be used to expand the clinical evaluation of Bellicum’s stem cell transplant, chimeric antigen receptor (CAR) T …
+1 212.937.4970